JP2022071130A5 - - Google Patents

Info

Publication number

JP2022071130A5

JP2022071130A5 JP2022032547A JP2022032547A JP2022071130A5 JP 2022071130 A5 JP2022071130 A5 JP 2022071130A5 JP 2022032547 A JP2022032547 A JP 2022032547A JP 2022032547 A JP2022032547 A JP 2022032547A JP 2022071130 A5 JP2022071130 A5 JP 2022071130A5

Authority

JP

Japan

Prior art keywords

antigen

composition

immune response

inducing

response according

Prior art date

2022-03-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims 24
• 102000036639 antigens Human genes 0.000 claims 24
• 108091007433 antigens Proteins 0.000 claims 24
• 230000028993 immune response Effects 0.000 claims 15
• 230000001939 inductive effect Effects 0.000 claims 14
• 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 4
• 239000002671 adjuvant Substances 0.000 claims 3
• 239000013604 expression vector Substances 0.000 claims 3
• 108020001507 fusion proteins Proteins 0.000 claims 3
• 102000037865 fusion proteins Human genes 0.000 claims 3
• 241000701806 Human papillomavirus Species 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 241000710886 West Nile virus Species 0.000 claims 2
• 210000004899 c-terminal region Anatomy 0.000 claims 2
• 230000002163 immunogen Effects 0.000 claims 2
• 201000001441 melanoma Diseases 0.000 claims 2
• 230000035772 mutation Effects 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
• 101710132601 Capsid protein Proteins 0.000 claims 1
• 101150029707 ERBB2 gene Proteins 0.000 claims 1
• 108700012234 Ebola virus VP24 Proteins 0.000 claims 1
• 241001115402 Ebolavirus Species 0.000 claims 1
• 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 claims 1
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
• 241000725303 Human immunodeficiency virus Species 0.000 claims 1
• 241000712431 Influenza A virus Species 0.000 claims 1
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
• 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims 1
• 230000005867 T cell response Effects 0.000 claims 1
• 101150036892 VP40 gene Proteins 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 210000004698 lymphocyte Anatomy 0.000 claims 1
• 210000003205 muscle Anatomy 0.000 claims 1
• 229940023146 nucleic acid vaccine Drugs 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 102000040430 polynucleotide Human genes 0.000 claims 1
• 108091033319 polynucleotide Proteins 0.000 claims 1
• 239000002157 polynucleotide Substances 0.000 claims 1
• 241000712461 unidentified influenza virus Species 0.000 claims 1